文献速递泌尿男性生殖肿瘤

局部前列腺癌大分割剂量递增IMRT与常规分割IMRT的随机试验

Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer.
PubMed 文献 · J Clin Oncol · 2018-08-14

这项随机试验纳入206例局部前列腺癌男性,对比大分割剂量递增IMRT(72 Gy/2.4 Gy/6周)与常规分割IMRT(75.6 Gy/1.8 Gy/8.4周)。

要点

  • 当大分割IMRT直肠接受65 Gy体积≤15%时,GI毒性仅8.6%。

核心结论

  • 局部前列腺癌患者接受大分割剂量递增IMRT较短疗程,癌症控制优于常规分割IMRT。

研究设计与样本

  • 随机试验纳入206例局部前列腺癌男性,随机分配至75.6 Gy/1.8 Gy/8.4周(CIMRT)或72 Gy/2.4 Gy/6周(HIMRT,假设α/β=1.5时生物等效于85 Gy/1.8 Gy)。
  • 失败定义为PSA失败(nadir+2 ng/mL)或启动挽救治疗,晚期毒性(放疗完成后≥90天)采用改良RTOG标准分级。

主要发现

  • 8年失败率HIMRT为10.7%(95%CI 5.8%-19.1%),CIMRT为15.4%(95%CI 9.1%-25.4%)。

关键数值与推荐

  • 失败定义:PSA失败(nadir+2 ng/mL)或启动挽救治疗。
  • 晚期毒性分级采用改良RTOG标准(放疗完成后≥90天)。

临床怎么用

  • 对局部前列腺癌,可考虑大分割剂量递增IMRT以缩短疗程并改善癌症控制。
  • 实施HIMRT时需关注直肠剂量体积,直肠接受65 Gy体积≤15%时GI毒性较低。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Hypofractionated radiotherapy delivers larger daily doses of radiation and may increase the biologically effective dose delivered to the prostate. We conducted a randomized trial testing the hypothesis that dose-escalated, moderately hypofractionated intensity-modulated radiation therapy (HIMRT) improves prostate cancer control compared with conventionally fractionated IMRT (CIMRT) for men with localized prostate cancer. PATIENTS AND METHODS: Men were randomly assigned to 75.6 Gy in 1.8-Gy fractions delivered over 8.4 weeks (CIMRT) or 72 Gy in 2.4 Gy fractions delivered over 6 weeks (HIMRT, biologically equivalent to 85 Gy in 1.8-Gy fractions assuming prostate cancer α-to-β ratio of 1.5). Failure was defined as prostate-specific antigen (PSA) failure (nadir plus 2 ng/mL) or initiation of salvage therapy. Modified Radiation Therapy Oncology Group criteria were used to grade late (≥ 90 days after completion of radiotherapy) GI and genitourinary toxicity. RESULTS: Most of the 206 men (72%) had cT1, Gleason score 6 or 7 (99%), and PSA level ≤ 10 ng/mL (90%) disease. Androgen deprivation therapy was received by 24%. With a median follow-up of 8.5 years, men treated with HIMRT experienced fewer treatment failures (n = 10) than men treated with CIMRT (n = 21; P = .036). The 8-year failure rate was 10.7% (95% CI, 5.8% to 19.1%) with HIMRT and 15.4% (95% CI, 9.1% to 25.4%) with CIMRT. There was no difference in overall survival ( P = .39). There was a nonsignificant increase in late grade 2 or 3 GI toxicity with HIMRT (8-year 5.0% v 12.6%; P = .08). However, GI toxicity was only 8.6% when rectal volume receiving 65 Gy of HIMRT was ≤ 15%. Late genitourinary toxicity was similar ( P = .84). There was no grade 4 toxicity. CONCLUSION: The results of this randomized trial demonstrate superior cancer control for men with localized prostate cancer who receive dose-escalated moderately hypofractionation radiotherapy while shortening treatment duration.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hoffman KE, Voong KR, Levy LB, et al. Randomized Trial of Hypofractionated, Dose-Escalated, Intensity-Modulated Radiation Therapy (IMRT) Versus Conventionally Fractionated IMRT for Localized Prostate Cancer. J Clin Oncol. 2018. PMID: 30106637. doi:10.1200/JCO.2018.77.9868

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。